The Technical Analyst
Fulcrum Therapeutics Inc [FULC]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Fulcrum Therapeutics Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
0.14% $7.07
America/New_York / 19 apr 2024 @ 10:19
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 437.88 mill |
| EPS: | -1.590 |
| P/E: | -4.45 |
| Earnings Date: | May 13, 2024 |
| SharesOutstanding: | 61.94 mill |
| Avg Daily Volume: | 0.636 mill |
| RATING 2024-04-18 |
|---|
| B- |
| Sell |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -4.45 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.76x |
| Company: PE -4.45 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$0.0454 (-99.36%) $-7.02 |
| Date: 2024-04-19 |
| Expected Trading Range (DAY) |
|---|
|
$ 6.35 - 7.79 ( +/- 10.23%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-03-18 | Horn Patrick Taylor | Buy | 400 000 | Stock Option (right to buy) |
| 2024-03-18 | Horn Patrick Taylor | Sell | 0 | No securities are beneficially owned |
| 2024-03-08 | Tourangeau Greg | Sell | 4 884 | Common Stock |
| 2024-03-04 | Sapir Alex | Buy | 43 360 | Common Stock |
| 2024-01-26 | Tourangeau Greg | Buy | 83 820 | Stock Option (right to buy) |
| INSIDER POWER |
|---|
| 20.82 |
| Last 98 transactions |
| Buy: 8 691 029 | Sell: 9 119 346 |
Forecast:
11:58 - $7.16
Live Trading Signals (every 1 min)
Forecast
1: 10:28 - $7.08
Forecast 2: 11:18 - $7.19
Forecast 3: 11:58 - $7.16
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $7.07 (0.14% ) |
| Volume | 0.0440 mill |
| Avg. Vol. | 0.636 mill |
| % of Avg. Vol | 6.91 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For FULC
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | buy | $8.33 | N/A | Active |
|---|
FULC
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Latest Press Releases
2024-03-22 16:30:00 - Press Release
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass., march 22, 2024 (globe newswire) -- fulcrum therapeutics, inc.® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to patrick horn, m.d., ph.d., the company's newly appointed chief medical officer. fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 inducement stock incentive plan, as amended, or the plan, as an inducement material to the new employees entering into employment with fulcrum in accordance with nasdaq listing rule 5635(c)(4).
2024-03-18 07:00:00 - Press Release
Fulcrum Therapeutics Appoints Patrick Horn M.d., Ph.d., As Chief Medical Officer
―industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards a potential regulatory submission and approval ―
2024-03-08 16:30:00 - Press Release
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Cambridge, mass., march 08, 2024 (globe newswire) -- fulcrum therapeutics, inc.® (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to two new employees. fulcrum granted stock options to purchase shares of the company's common stock pursuant to the company's 2022 inducement stock incentive plan, as amended, or the plan, as an inducement material to the new employees entering into employment with fulcrum in accordance with nasdaq listing rule 5635(c)(4).
2024-03-05 08:00:00 - Press Release
Fulcrum Therapeutics To Participate At The Leerink Partners Global Biopharma Conference
Cambridge, mass., march 05, 2024 (globe newswire) -- fulcrum therapeutics, inc.® (the “company”) (nasdaq: fulc), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will present a corporate overview at the leerink partners global biopharma conference, being held in miami, fl on wednesday, march 13, 2024 at 9:20 a.m. et. management will also participate in one-on-one investor meetings.
2024-02-27 07:00:00 - Press Release
Fulcrum Therapeutics Announces Recent Business Highlights And Financial Results for Fourth Quarter And Full Year 2023
― on track to report topline data for phase 3 reach trial of losmapimod in facioscapulohumeral m uscular dystrophy (fshd) in the fourth quarter of 2024 ―
Latest News
2024-04-15 12:54:18 - InvestorPlace
Biotech on a Budget: 7 Stocks Under $10 With Huge Potential
The broader medical therapeutic sector is already volatile so it stands to reason in some sense to consider under-$10 biotech stocks. Imagine you acquired shares of a popular, richly priced enterprise, only for the underlying security to suffer due to a poor clinical result.
2024-02-27 12:30:20 - Seeking Alpha
Fulcrum Therapeutics, Inc. (FULC) Q4 2023 Earnings Call Transcript
2024-02-27 09:11:04 - Zacks Investment Research
Fulcrum Therapeutics, Inc. (FULC) Reports Q4 Loss, Tops Revenue Estimates
Fulcrum Therapeutics, Inc. (FULC) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.50 per share a year ago.
2023-11-09 08:00:00 - GlobeNewsWire
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will participate in the following upcoming investor conferences:
2023-11-07 10:12:07 - Seeking Alpha
Fulcrum Therapeutics, Inc. (FULC) Q3 2023 Earnings Call Transcript
Fulcrum Therapeutics, Inc. (NASDAQ:FULC ) Q3 2023 Earnings Conference Call November 8, 2023 8:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Financial Officer Iain Fraser - Interim Chief Medical Officer Conference Call Participants Benazir Ali - Stifel Joe Schwartz - Leerink Partners Edward Tenthoff - Piper Sandler Matthew Hagood - Oppenheimer Operator Good morning and welcome to Fulcrum Therapeutics Third Quarter 2023 Financial Results and Business Update Conference Call. Currently, all participants are in a listen-only mode.
2023-10-31 08:50:00 - GlobeNewsWire
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that its third quarter 2023 financial results will be released on Tuesday, November 7, 2023 before the U.S. financial markets open. Management will host a conference call and webcast at 8:00 a.m. ET to discuss the results and provide an update on recent corporate developments.
2023-09-25 14:10:47 - Seeking Alpha
An Updated View On Fulcrum Therapeutics
Fulcrum Therapeutics, Inc. has had some key potential catalysts resolved positively recently. These included the FDA lifted the clinical hold on Fulcrum's sickle-cell disease candidate, allowing the company's Phase 1b trial to move forward. The company has also made progress in filling management positions and has initiated a Phase 3 study for its late-stage candidate, Losmapimod.
2023-09-22 08:00:00 - GlobeNewsWire
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference, being held in New York, NY on Thursday, September 28, 2023 at 8:35 a.m. ET.
2023-08-24 09:46:09 - Zacks Investment Research
Fulcrum (FULC) Up as FDA Lifts Clinical Hold on SCD Candidate
Fulcrum's (FULC) shares surge as the FDA lifts the clinical hold it had earlier placed on its pipeline candidate FTX-6058, to treat patients with sickle cell disease.
2023-08-22 14:59:45 - Schaeffers Research
Options Traders Blast Biotech Stock on FDA Buzz
Fulcrum Therapeutics Inc (NASDAQ:FULC) is up 49.7% to trade at $5.87 at last glance -- its highest levels since March -- after the U.S. Food and Drug Administration (FDA) lifted its clinical hold on the biotech name's application for its sickle cell disease treatment.